Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

Gliomas are ranked as the most aggressive brain tumors; they show a high frequency of invasion mediators such as angiogenic factors and chemokines (small-sized proteins, produced and released locally, intended for localized action) [1‐3].

Simultaneous evaluation of multiple proteins in serum and cerebrospinal fluid allows for the identification of novel circulating biomarker panels helpful in disease diagnosis and treatment [4]. Therefore, in the last few years, proteomic approaches have been used to indicate potential cytokines, chemokines, and angiogenic factors for diagnosis and/or progression of primary brain tumors [1, 5, 6]. Using throughput xMAP technology, Albulescu et al. identified serum profiles of cytokines and angiogenic factors (IL-6, IL-1β, IL-2, IL-10, TNF-α, VEGF, FGF-2, and GM-CSF) altered in glioblastoma patients [1]. The authors highlighted that the evaluation of biomarker panels is more appropriate than single molecule analysis [1]. Studies by Popescu et al. also indicated the role of simultaneous identification of proteomic signature in the diagnosis and treatment of brain tumors, as they, by means of SELDI-ToF MS technology, indicated serum S100A8, S100A9, and CXCL4 proteins as a potential candidate for glioblastoma biomarkers [5]. A bio-plex system multi-marker screening by Nijaguna et al., of circulating serum biomarkers in glioma patients, indicated 18 cytokines (interleukins: -2, -3, -4, -6, -7, -10, -12, -17, -15, MIP1 α, LIF, TNF-α, FGF basic, GM-CSF, IFN-γ, IL1Rα, SCGFβ, and βNGF) discriminating glioma patients from healthy individuals [6]. The authors also proposed that the above-mentioned cytokines may be useful in monitoring response to the treatment and glioma recurrence [6].

Monocyte chemotactic protein-1 (MCP-1/CCL2) has been found in different tumor samples and may be recognized as a potential regulator of cancer progression [7, 8]. In vivo studies showed that a significant source of CCL2 is tumor epithelium [8]. Additionally, tumor cells themselves may be a major source of this protein. Expression and localization of mRNA and protein for CCL2 in human malignant glioma was found by Takeshima et al. [7]. Studies of other authors revealed that antibody-mediated blockade of CCL2 had an influence on the survival prolongation of glioma cells in mice and in humans [9]. These findings suggest that CCL2 may be a potential therapeutic target.

Interleukin-8 (IL-8), also known as CXCL8, is a member of the CXC family of chemokines [10]. Similar to the CCL2, IL-8 may be produced by the tumor cells itself and/or released by immune cells activated in response to tumor cell growth [11]. During inflammation, IL-8 takes part in carcinogenesis by acting directly on epithelial cells via NFKB1 pathway signaling. Additionally, IL-8 expression by tumor cells stimulates cancer cell proliferation, migration, as well as invasion [11, 12].

Intercellular adhesion molecule 1 (ICAM-1/CD54) is a nearly ubiquitous transmembrane glycoprotein. Elevated levels of this protein were related with certain malignancies [13]. Soluble ICAM-1 (sICAM-1) has been recognized as an indicator of vascular endothelial cell activation or damage [14]. It also assumes an inhibiting role for transmembrane ICAM-1-mediated activities such as the sensitivity of tumor cells to NK cell-mediated lysis [15].

In the last few years, great effort has been put into searching for diagnostic, prognostic, predictive, and therapeutic response biomarkers in glioma patients [16]; however, so far, no single circulating biomarker has been used in routine practice for management of these patients [17]. The search for these kinds of biomarkers still represents an exciting research area; therefore, the aim of the current study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and ICAM-1 in patients with neuroepithelial tissue tumors as compared to non-tumoral patients, with no history of cancer as a comparative group. To exclude possible fluctuations of the blood-brain barrier and the blood-CSF barrier, we also calculated the indexes for each protein tested by referring the obtained results in CSF to values in serum. It would be of great interest to establish biomarkers measurable in biological fluids distinguishing patients with CNS tumors from non-tumoral subjects. Moreover, our studies may highlight potential factors which may indicate a direction for targeted therapy.

Regardless of the parameter tested and the patient group (CNS brain tumors or non-tumoral individuals), statistically relevant differences were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested (P < 0.05). Significant differences were found between the study groups in CSF for IL-8, while in serum, differences were obtained for CCL2 and sICAM-1 (Table 2). Correlation coefficient analysis did not reveal a relation between concentrations of proteins tested in the serum with values in the CSF, except for moderate correlations for IL-8 in CNS brain tumors (R = 0.50, P = 0.024) and for CCL2 in the non-tumoral group (R = 0.45, P = 0.044).

According to the literature, free chemokine concentrations in normal human serum are mostly below the lower limit of detection. An explanation for this may be the presence of immune complexes in which the epitope is embedded [21].

However, our study revealed detectable concentrations, above the lower limit of detection, for IL-8 and CCL2 in all patients’ samples, regardless of the material (serum/CSF) or study group (CNS brain tumors/non-tumoral subjects) analyzed.

Also, serum sICAM-1 concentrations were detected in all the tested samples, which was previously confirmed by the studies of Nano et al., as they revealed that sICAM-1 serum levels were not significantly increased in GBL and astrocytoma patients compared with another type of tumor (lung and kidney cancer) [13]. Surprisingly, CSF levels for the adhesion molecule sICAM-1 were below the lower limit of the test sensitivity in most of the samples analyzed (we found sICAM-1 concentrations in only 6 of the 20 CSF samples of CNS brain tumor patients and in only 3 of the 20 CSF of the control samples).

Rieckmann et al. found a low-level expression of mRNA for sICAM in human cerebral endothelial cells (obtained from early post-mortem human brains), U251 glioma cells, blood mononuclear cells, and cerebrospinal fluid cells of patients with aseptic meningitis [22]. Additionally, they found that upon stimulation with LPS or TNF-α, cerebral endothelial cells and U251 glioma cells were capable of releasing sICAM-1 into the culture supernatant [22].

So far, detectable sICAM-1 concentrations in CSF have been found by Brandsma et al. [23] and Tiberti et al. [24]; however, the study populations were leptomeningeal metastases subjects and human African trypanosomiasis individuals, respectively. Moreover, Brandsma et al. tested sICAM-1 levels by means of multiplex immuno-assay (MIA) and paired antibodies from different commercial vendors [23], thus we could not estimate the concentrations of the targeted protein and we performed the experiment with the dilution factor recommended by the manufacturer. Based on the obtained results, we hypothesize, that for sICAM-1 analysis in the CSF, we did not use the appropriate dilution factor and the best way to test the sICAM-1 concentrations in the CSF is to analyze undiluted samples. However, we could not re-test undiluted CSF samples because of a lack of material in order to confirm this. Despite the inappropriate dilution factor, the second reason for the failed sICAM-1 concentrations results in the CSF might be the sensitivity of the assay kit (there is a possibility that more sensitive assays are needed).

Current studies have revealed, that regardless of the parameter tested and the patient group, statistical differences were to be found between concentrations obtained in CSF compared to values obtained in serum for all proteins measured. Significant differences were found between the study groups in CSF for IL-8, while in serum, differences were obtained for CCL2 and sICAM-1. Our findings indicate altogether, that for individual biomarkers (IL-8 and CCL2, sICAM-1), the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested.

Our study revealed statistically increased CSF IL-8 concentrations in CNS brain tumor patients as compared to non-tumoral subjects, which indicates that this chemokine may be synthesized within the CNS tissue during astrocytic tumor development and IL-8-related neuroinflammation can have a significant influence on glioblastoma (GBM) progression. Studies indicated that IL-8 is secreted by activated monocytes and macrophages expressed in microglia and it is a proangiogenic factor in gliomas [25‐28]. Moreover, enhanced secretion of IL-8 by glioma cells was also reported by Yeung et al. [29]. IL-8 was also inversely correlated with GBM patients’ survival [30]. GBM cells, which secrete IL-8, promote angiogenesis and microvascular endothelial permeability [9]. IL-8 can also regulate GBM associated “cancer stem cells” (CSCs) and was associated with tumor grade in astrocytic neoplasms [31]. IL-8 induces the growth and migration of CSCs via receptors CXCR1 and CXCR2. Observations concerning human microvascular ECs revealed that the blockade of either receptor decreases IL-8-related chemotaxis. de la Iglesia et al. showed that in PTEN-deficient glioblastoma cells, repression of IL-8 can inhibit glioma cell proliferation and invasiveness [32].

Originally, CCL2 has been purified to homogeneity and cDNA, then cloned from the glioma cell line [3, 8]. The production of CCL2 by different types of human malignant glioma cell lines has been well documented. It was also noted that malignant glioma cells produce more CCL2 compared to other tumor cell lines, such as melanoma or malignant fibrous histiocytoma [33].

According to best knowledge, our study is the second which evaluated CCL2 concentrations in the CSF of patients with CNS brain tumors. However, results of our group are in disagreement with the reports of Kuratsu et al., which revealed that CCL2 concentrations in CSF samples from malignant glioma subjects were statistically higher in comparison to individuals with benign glioma, as well as compared to non-tumoral patients [33]. We did not reveal significant differences for CSF CCL2 between the brain tumor group compared to patients with no tumor. Moreover, CCL2 concentrations revealed a tendency to be lower in brain tumors as compared to non-tumoral individuals. In our opinion, the discrepancies between the results of these two studies may result from the following: (1) different antibodies applied by means of ELISA (Kuratsu et al. used rabbit polyclonal antibody and mouse monoclonal antibody (clone E11) against human CCL2); our group applied a ready-to-use ELISA plate coated with a monoclonal antibody specific for human and recombinant CCL2 from a well-known vendor (R&D Systems) and/or (2) not homogenous CSF samples (Kuratsu et al. collected CSF to analyze from different CNS spaces (lumbar interspace/cisternography by drainage during the surgery/directly from cisterns or brain ventricles), while our group collected all CSF samples from the supratentorial subarachnoid space and/or (3) a different number of non-tumoral subjects (Kuratsu et al. N = 7, our group N = 20). We have one more explanation as to why in our study, CSF CCL2 concentrations were lower as compared to non-tumoral subjects: this may be due to the fact that CNS astrocytic tumors, which grow inside the tumor mass, may not have the possibility to make contact with the CSF and thus CCL2 cannot be released into the cerebrospinal fluid.

In our study, serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors as compared to the non-tumoral group. From both of the proteins tested in the serum, a higher clinical significance was revealed for CCL2. However, the CNS is actually still not recognized as an immune privileged site, as there is no strong evidence in the available literature that the protective brain barriers are meaningfully altered in malignant gliomas. Therefore, blood CNS tumor biomarkers, defined as measurable indicators of diseases, their progress and response to therapeutic intervention, are of great clinical value. Biomarkers, which may be detected and measured in the peripheral blood, are of important interest due to the fact that blood is easy to obtain and the blood collection procedure is not as traumatic as lumbar puncture and involves only momentary discomfort to the patient.

In conclusion, our results support the assumption that CSF IL-8 concentrations could play a crucial role in predicting the presence of astrocytic tumors. However, there is a need for further studies, if IL-8 may also be recognized as a helpful biomarker assessing patients’ response to the applied therapy. From the biomarkers tested in the blood, CCL2 seems to have clinical utility; therefore, for individual biomarkers (IL-8 and CCL2, sICAM-1), the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. To sum up, increased CSF IL-8 with decreased serum CCL2 gives a biomarker pattern, which in combination with a conventional therapeutic strategy may be helpful in the management of CNS astrocytic brain tumors.